Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00514962 | Stomach | CSG | positive regulation of stress fiber assembly | 9/1034 | 52/18723 | 1.98e-03 | 2.07e-02 | 9 |
GO:004328021 | Stomach | CSG | positive regulation of cysteine-type endopeptidase activity involved in apoptotic process | 16/1034 | 129/18723 | 2.00e-03 | 2.08e-02 | 16 |
GO:190289321 | Stomach | CSG | regulation of pri-miRNA transcription by RNA polymerase II | 9/1034 | 54/18723 | 2.60e-03 | 2.51e-02 | 9 |
GO:001081021 | Stomach | CSG | regulation of cell-substrate adhesion | 23/1034 | 221/18723 | 2.65e-03 | 2.55e-02 | 23 |
GO:004217711 | Stomach | CSG | negative regulation of protein catabolic process | 15/1034 | 121/18723 | 2.74e-03 | 2.62e-02 | 15 |
GO:006161421 | Stomach | CSG | pri-miRNA transcription by RNA polymerase II | 9/1034 | 55/18723 | 2.96e-03 | 2.77e-02 | 9 |
GO:005189311 | Stomach | CSG | regulation of focal adhesion assembly | 10/1034 | 66/18723 | 3.18e-03 | 2.92e-02 | 10 |
GO:009010911 | Stomach | CSG | regulation of cell-substrate junction assembly | 10/1034 | 66/18723 | 3.18e-03 | 2.92e-02 | 10 |
GO:007048221 | Stomach | CSG | response to oxygen levels | 32/1034 | 347/18723 | 3.20e-03 | 2.92e-02 | 32 |
GO:009025711 | Stomach | CSG | regulation of muscle system process | 25/1034 | 252/18723 | 3.39e-03 | 3.06e-02 | 25 |
GO:000166621 | Stomach | CSG | response to hypoxia | 29/1034 | 307/18723 | 3.46e-03 | 3.12e-02 | 29 |
GO:003432921 | Stomach | CSG | cell junction assembly | 37/1034 | 420/18723 | 3.50e-03 | 3.15e-02 | 37 |
GO:000691311 | Stomach | CSG | nucleocytoplasmic transport | 28/1034 | 301/18723 | 4.97e-03 | 4.10e-02 | 28 |
GO:005116911 | Stomach | CSG | nuclear transport | 28/1034 | 301/18723 | 4.97e-03 | 4.10e-02 | 28 |
GO:000725411 | Stomach | CSG | JNK cascade | 18/1034 | 167/18723 | 5.10e-03 | 4.17e-02 | 18 |
GO:19038296 | Stomach | CSG | positive regulation of cellular protein localization | 26/1034 | 276/18723 | 5.64e-03 | 4.50e-02 | 26 |
GO:001092111 | Stomach | CSG | regulation of phosphatase activity | 11/1034 | 84/18723 | 6.37e-03 | 4.92e-02 | 11 |
GO:0098586 | Stomach | CSG | cellular response to virus | 11/1034 | 84/18723 | 6.37e-03 | 4.92e-02 | 11 |
GO:0042176113 | Thyroid | PTC | regulation of protein catabolic process | 231/5968 | 391/18723 | 4.76e-29 | 2.14e-26 | 231 |
GO:0072594112 | Thyroid | PTC | establishment of protein localization to organelle | 244/5968 | 422/18723 | 1.18e-28 | 4.97e-26 | 244 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SMAD3 | SNV | Missense_Mutation | novel | c.1094N>C | p.Gln365Pro | p.Q365P | P84022 | protein_coding | deleterious(0.01) | possibly_damaging(0.882) | TCGA-A2-A04R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | SD |
SMAD3 | SNV | Missense_Mutation | rs779602560 | c.1145C>T | p.Ala382Val | p.A382V | P84022 | protein_coding | deleterious(0.04) | benign(0.167) | TCGA-A2-A0T6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
SMAD3 | SNV | Missense_Mutation | rs863223765 | c.278N>A | p.Arg93Gln | p.R93Q | P84022 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E2-A152-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | PD |
SMAD3 | SNV | Missense_Mutation | novel | c.611N>A | p.Ser204Tyr | p.S204Y | P84022 | protein_coding | tolerated(0.09) | benign(0) | TCGA-E9-A244-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
SMAD3 | SNV | Missense_Mutation | | c.68N>G | p.Gln23Arg | p.Q23R | P84022 | protein_coding | deleterious(0.01) | benign(0.091) | TCGA-EW-A1IZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
SMAD3 | insertion | Nonsense_Mutation | novel | c.263_264insTCTCTACTAAAAATACAAAAACAAAATTAG | p.Tyr88_Cys89insLeuTyrTerLysTyrLysAsnLysIleSer | p.Y88_C89insLY*KYKNKIS | P84022 | protein_coding | | | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
SMAD3 | SNV | Missense_Mutation | rs863223736 | c.728N>A | p.Arg243His | p.R243H | P84022 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SMAD3 | SNV | Missense_Mutation | rs773543026 | c.730G>A | p.Val244Ile | p.V244I | P84022 | protein_coding | tolerated(0.12) | benign(0.395) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
SMAD3 | SNV | Missense_Mutation | rs387906850 | c.859C>T | p.Arg287Trp | p.R287W | P84022 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
SMAD3 | SNV | Missense_Mutation | | c.384G>C | p.Gln128His | p.Q128H | P84022 | protein_coding | deleterious(0.02) | possibly_damaging(0.528) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4088 | SMAD3 | DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX | | GNF-PF-1295 | CHEMBL579837 | |
4088 | SMAD3 | DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX | | HELENALIN | HELENALIN | |
4088 | SMAD3 | DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX | | TRICLOCARBAN | TRICLOCARBAN | |
4088 | SMAD3 | DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX | | DNDI1417601 | CHEMBL1503729 | |
4088 | SMAD3 | DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX | | CID 663143 | CHEMBL1342336 | |
4088 | SMAD3 | DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX | | BISINDOLYLMALEIMIDE IX | BISINDOLYLMALEIMIDE IX | |
4088 | SMAD3 | DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX | | MITOXANTRONE | MITOXANTRONE | |
4088 | SMAD3 | DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX | | NSC-724440 | CHEMBL515617 | |
4088 | SMAD3 | DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX | | GNF-PF-1134 | CHEMBL600694 | |
4088 | SMAD3 | DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX | | AZACITIDINE | AZACITIDINE | |